Partner Emeritus at Big Pi Ventures
Check size: No current personal check range: Aristos is Partner Emeritus and an official 2025 biography says he is not involved with Big Pi's later funds. Big Pi's current platform range is €0.5M–€30M across funds, but should not be attributed to him.
Aristos' historical investment lens combines strong technology, team, and market position with realistic commercialization targets. He favors research-based ventures that can bridge academia and industry, secure early adopters beyond a small home market, and use seed or Series A capital to build enough traction for international follow-on funding. His long private-equity career also brings attention to governance, business fundamentals, and social or economic impact.
For a research venture, connect the scientific result to a useful product, credible development milestones, IP or technical defensibility, early-adopter evidence, regulatory or clinical path where relevant, and an international market. Be realistic about capital and timelines, show a balanced technical and commercial team, and explain how seed or Series A progress will unlock global follow-on investors.
He is described as enjoying new business ideas, optimistic entrepreneurs, critical thinking, leading-edge research, and realistic targets. His investment comments emphasize the combined strength of technology, team, and market position, particularly where innovation can materially improve lives or reduce system costs.
His public views imply caution toward research without a route to market, unrealistic milestones, weak teams or market positions, products confined to a small domestic market, companies that wait too long to build international funding relationships, and impact claims disconnected from a sustainable business model.
Require a defensible technology, a team capable of product and commercialization execution, and a sufficiently strong market position or entry wedge; weakness in any one leg limits venture-scale potential.
Map the steps from leading-edge research through product validation and early adopters to the traction needed for international Series B capital, using realistic technical, regulatory, commercial, and financing milestones.
“We like to invest in companies which have strong technologies, teams and market positions.”
— https://www.orthoson.com/assets/uploads/OrthoSon_Series_A_28_04_22_FINAL.pdf
Research-based ventures need to be evaluated on venture-scale criteria and realistic targets that connect academic innovation to investable businesses.
CEE can turn abundant STEM talent into globally competitive deep-tech companies by improving academic-industry collaboration, cultivating corporate early adopters, and preparing startups for international growth capital.
+ 18 more investments. View fund →